uniQure price target raised to $28 from $14 at Stifel

Stifel analyst Paul Matteis raised the firm’s price target on uniQure (QURE) to $28 from $14 and keeps a Buy rating on the shares. The firm reiterated its Buy view following the company’s Q1 update, where the company remains on track to have a Type B meeting with the FDA in 2Q26. While the firm isn’t expecting an imminent FDA 180, what will be interesting here is tot see how uniQure can try to preserve some optionality with the four-year data cut, the analyst tells investors in a research note.